Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Tech and Science > Experimental Drug Helped Cancer Patients Live 40% Longer in Clinical Trial : ScienceAlert
Tech and Science

Experimental Drug Helped Cancer Patients Live 40% Longer in Clinical Trial : ScienceAlert

Last updated: June 3, 2025 5:15 am
Share
Experimental Drug Helped Cancer Patients Live 40% Longer in Clinical Trial : ScienceAlert
SHARE

An Exciting Breakthrough in Stomach Cancer Treatment

An innovative new treatment for tackling some of the toughest stomach cancers has shown remarkable promise in a phase 2 clinical trial, leading to significant improvements in tumor shrinkage and survival rates.

The treatment involves a form of CAR T cell immunotherapy, where the body’s own immune cells are extracted, trained to target cancer cells more effectively, and then reintroduced into the bloodstream.

Known as satricabtagene autoleucel, or satri-cel, this therapy targets the CLDN18.2 protein that certain tumors utilize for growth. Patients who received satri-cel in the trial lived approximately 40 percent longer on average.

Researchers from various institutions across China conducted the trial, which involved 156 participants with gastric or gastroesophageal junction cancer that had not responded to at least two previous treatments. These patients were essentially running out of options before participating in the trial.

Survival rate graph
One of the benefits of the treatment was living for longer. (Qi et al., The Lancet,. 2025)

In the satri-cel group, patients had a median average survival of 7.92 months compared to 5.49 months in the control group. Notably, 22 percent of satri-cel patients experienced significant tumor shrinkage, in contrast to just 4 percent of control patients.

The median time before cancer progression was 3.25 months with satri-cel and 1.77 months without, showcasing the treatment’s efficacy across various metrics.

“This brings new hope to patients with otherwise medically untreatable conditions,” remarked oncologist Lin Shen from Beijing Cancer Hospital.

While satri-cel treatment led to significant side effects, including a drop in blood cell counts, researchers believe these side effects are manageable.

CAR T cell therapy has already demonstrated effectiveness in treating blood cancers, and promising results are emerging for solid tumors such as brain cancer and pancreatic cancer. The success seen in treating stomach cancers adds to this growing list of achievements in cancer research.

See also  You don't want to miss out on the five best headphone deals of October Prime Day, ending soon

While this treatment is not a cure, it represents a significant advancement in managing cancer tumors by enhancing the body’s immune response against malignant growths.

“We are further exploring satri-cel’s potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients’ survival, and ultimately pursue potential cures,” Shen added.

The research findings have been published in The Lancet.

TAGGED:cancerclinicalDrugExperimentalhelpedLiveLongerpatientsScienceAlertTrial
Share This Article
Twitter Email Copy Link Print
Previous Article How Life’s Hardest Moments Became My Greatest Teachers How Life’s Hardest Moments Became My Greatest Teachers
Next Article American Eagle Outfitters swings to Q1 loss on higher costs, sluggish demand American Eagle Outfitters swings to Q1 loss on higher costs, sluggish demand
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

The Sacred Significance of San Judas Tattoos

Exploring the Spiritual Depth of San Judas Tattoos Among religious tattoos, few symbols resonate as…

September 25, 2025

Mpox: How deadly is the virus and what treatments are available?

A health worker assesses a suspected case of mpox in North Kivu, Democratic Republic of…

August 25, 2024

This Pennsylvania settlement could set the standard for preventing tiny plastic pellet pollution

Given the detrimental effects of plastics on the environment and human health, the legal victory…

September 22, 2025

‘Amadeus’ Teaser: Will Sharpe’s Mozart and Paul Bettany’s Salieri Face Off in Sky Series

Will Sharpe takes on the role of Mozart, while Paul Bettany portrays Salieri in the…

October 14, 2025

Hurricanes HC Rod Brind’Amour makes his opinion crystal clear on Panthers’ HC Paul Maurice’s controversial hand-shake decision

June 3, 2025

You Might Also Like

Nanotyrannus Isn’t a Juvenile T-Rex—It’s a Separate Dinosaur
Tech and Science

Nanotyrannus Isn’t a Juvenile T-Rex—It’s a Separate Dinosaur

October 31, 2025
How Much Does Grocery Delivery App Development Cost in 2025?
Tech and Science

How Much Does Grocery Delivery App Development Cost in 2025?

October 31, 2025
Once Again A Blood Pressure Medication Recall For Cancer Concerns
Health and Wellness

Once Again A Blood Pressure Medication Recall For Cancer Concerns

October 31, 2025
Boy’s body was mummified and turned green by a copper coffin
Tech and Science

Boy’s body was mummified and turned green by a copper coffin

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?